LU84952A1 - Arzneimittel mit analgetischer wirkung - Google Patents
Arzneimittel mit analgetischer wirkung Download PDFInfo
- Publication number
- LU84952A1 LU84952A1 LU84952A LU84952A LU84952A1 LU 84952 A1 LU84952 A1 LU 84952A1 LU 84952 A LU84952 A LU 84952A LU 84952 A LU84952 A LU 84952A LU 84952 A1 LU84952 A1 LU 84952A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- content
- fatty acids
- esters
- drugs
- acid esters
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title 1
- 150000002148 esters Chemical class 0.000 claims description 7
- 229930194542 Keto Natural products 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- -1 keto fatty acids Chemical class 0.000 claims description 5
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 5
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical class CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 3
- FGDSJTQKTCFIFZ-UHFFFAOYSA-N C(CCC)(=O)O.C(CCC)(=O)O.C(CCC)(=O)O.OCC(O)CO Chemical class C(CCC)(=O)O.C(CCC)(=O)O.C(CCC)(=O)O.OCC(O)CO FGDSJTQKTCFIFZ-UHFFFAOYSA-N 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical class CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 150000001656 butanoic acid esters Chemical class 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 description 7
- 239000000730 antalgic agent Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- DNTVKOMHCDKATN-UHFFFAOYSA-N pyrazolidine-3,5-dione Chemical class O=C1CC(=O)NN1 DNTVKOMHCDKATN-UHFFFAOYSA-N 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3229955 | 1982-08-12 | ||
| DE19823229955 DE3229955A1 (de) | 1982-08-12 | 1982-08-12 | Arzneimittel mit analgetischer wirkung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU84952A1 true LU84952A1 (de) | 1983-12-28 |
Family
ID=6170655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU84952A LU84952A1 (de) | 1982-08-12 | 1983-08-04 | Arzneimittel mit analgetischer wirkung |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE897536A (OSRAM) |
| DE (1) | DE3229955A1 (OSRAM) |
| FR (1) | FR2531859A1 (OSRAM) |
| LU (1) | LU84952A1 (OSRAM) |
| NL (1) | NL8302830A (OSRAM) |
| SE (1) | SE8304331L (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8803141L (sv) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Naeringsmedel foer maenniskor och djur |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| EP1778615A4 (en) | 2004-07-20 | 2010-01-06 | Btg Int Ltd | OLIGOMERE KETONE COMPOUNDS |
-
1982
- 1982-08-12 DE DE19823229955 patent/DE3229955A1/de not_active Withdrawn
-
1983
- 1983-08-04 LU LU84952A patent/LU84952A1/de unknown
- 1983-08-09 SE SE8304331A patent/SE8304331L/ not_active Application Discontinuation
- 1983-08-11 NL NL8302830A patent/NL8302830A/nl not_active Application Discontinuation
- 1983-08-11 FR FR8313232A patent/FR2531859A1/fr active Granted
- 1983-08-12 BE BE0/211358A patent/BE897536A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2531859A1 (fr) | 1984-02-24 |
| SE8304331L (sv) | 1984-02-13 |
| BE897536A (fr) | 1983-12-01 |
| DE3229955A1 (de) | 1984-02-16 |
| FR2531859B3 (OSRAM) | 1985-03-08 |
| NL8302830A (nl) | 1984-03-01 |
| SE8304331D0 (sv) | 1983-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69621756T2 (de) | Betahydroxybuttersäure oder Acetoessigsäure oder deren Salze oder Ester zur Verwendung zur Verbesserung der Gehirnfunktion | |
| DE3413052A1 (de) | Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| EP0254869A2 (de) | Verwendung von Aryloxycarbonsäure-Derivaten gegen dermatologische Erkrankungen | |
| DE69615984T2 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
| DE60132008T2 (de) | Cetylmyristat und cetylpalmitat zur behandlung von ekzemen und/oder psoriasis | |
| EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE3603564A1 (de) | Pharmazeutische praeparate mit analgetrischer wirksamkeit, sowie deren herstellung und verwendung | |
| EP0318891B1 (de) | Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren | |
| CH695983A5 (de) | Tetraiodthyropropionsäure oder Tetraiodthyroessigsäure zur Herstellung eines dermatologischen Präparates. | |
| DE69306990T2 (de) | Physostigmin-Derivate, ihre Verwendung und sie enthaltende pharmazeutische Formulierungen | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| EP0817623B1 (de) | Arzneistoffe zur selektiven bekämpfung von tumorgewebe | |
| DE69407684T2 (de) | Verwendung von L-Carnitine oder Acyl-L-Carnitinen und Valproat zur Behandlung von Anfallserkrankungen | |
| LU84952A1 (de) | Arzneimittel mit analgetischer wirkung | |
| DE2126533A1 (de) | Verfahren zur Herstellung pharma zeutischer Zubereitungen | |
| EP0803254A1 (de) | Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel | |
| EP0521925B1 (de) | Verwendung von efeu zur topischen behandlung der psoriasis | |
| DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
| EP1131101B1 (de) | Khellin-zubereitung und deren verwendung zur topischen therapie | |
| DE2518509C3 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
| EP0484581B1 (de) | Verwendung von Thromboxan-A2-Antagonisten zur Verhinderung von degenerativen Vorgängen im penilen Gewebe | |
| DE2753140C2 (de) | Arzneimittel zur Behandlung von Magengeschwüren | |
| DE3880579T2 (de) | Pharmazeutische zusammensetzungen zur behandlung der verstopfung der luftwege. | |
| DE60210804T2 (de) | Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit |